Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Canada joins EU on the biosimilars train

This article was originally published in The Gold Sheet

Executive Summary

Health Canada has issued a "Draft Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs). The document guides sponsors on information and regulatory requirements for subsequent entry biologic products in Canada. The concept of a SEB applies to all biologic drug submissions in which the sponsor would, based on demonstrated similarity to a reference biologic product, rely in part on publicly available information from a previously approved biologic drug in order to present a reduced clinical package as part of the submission. The EU has allowed approval of biosimilar products since 2005. Biosimilar legislation is currently pending in the U.S. and is being held up by legislators' concerns on extended data exclusivity for brand companies and coming to terms with what should constitute a biosimilar drug



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts